Halozyme Therapeutics, Inc.
Strong FundamentalsStrong FundamentalsRevenue growing 42% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (116/wk), no spike$110.40-1.0%YTD+63.0%1Y+50.5%
Price updated 4h ago·X counts updated 3d ago
On X
The complete picture of $HALO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
116X posts · last 7 days
Chatter Meter
1×
How loud $HALO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $HALO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $HALO.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $HALO
Partial — Proprietary ENHANZE drug delivery platform converts IV biologics into subcutaneous injections; licensed to 15+ pharma partners including J&J and Roche.
Top industry ETF
$IBBiShares Biotechnology ETF
+24.1%YTD
+45.8%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
26.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
23.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
57.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
7.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
6.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
126%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
76.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
9.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$2.28$1.79+27.4%
Q1 2026May 11, 2026$1.60$1.55+3.2%
Q4 2025Feb 17, 2026$-0.24$2.15-111.2%
Q3 2025Nov 3, 2025$1.72$1.63+5.5%
Next earningsMon, Nov 2·consensus EPS $2.25
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$376.7M+42.2%71.1%49.0%$1.27$176.3M
Q4 FY25$451.8M+51.6%77.4%56.3%$-1.20$217.6M
Q3 FY25$354.3M+22.1%79.4%61.5%$1.49$175.6M
Q2 FY25$325.7M+40.8%80.3%62.2%$1.36$98.1M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$1.8B$1.7B – $1.9B$8.41$8.40 – $8.426
FY27$2.1B$2.0B – $2.1B$10.30$9.96 – $10.626
FY28$2.2B$2.1B – $2.4B$11.72$11.03 – $12.205
FY29$2.1B$2.0B – $2.3B$10.71$9.84 – $11.422
FY30$1.9B$1.8B – $2.0B$9.38$8.62 – $10.002
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.90%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+43.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 117.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.885-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KMaterial agreementSep 228-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale
AI summary
3New insider — initial holdingsAug 213
AI summary
8-KOfficer or director changeAug 188-K — Item 5.02: Officer or director change
AI summary
8-KOfficer or director changeJul 28-K — Item 5.02: Officer or director change
AI summary
3New insider — initial holdingsJun 93
AI summary
8-KShareholder voteMay 78-K — Item 5.07: Shareholder vote
AI summary
8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change
8-KCharter amendmentApr 248-K — Item 5.03: Charter amendment
+ 7 other (2 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks · 1 13G) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Halozyme Announces Appointment of Jim Daly to its Board of DirectorsWhy Women-Run Companies Deserve a Place in Your PortfolioHalozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Here’s WhyHead to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 4 · last 7 days